![Drug Repurposing](https://endd.med.upenn.edu/wp-content/uploads/2023/08/drug-repurposing-1024x683.jpg)
Team Leader:
![repurposing scheme](https://endd.med.upenn.edu/wp-content/uploads/2023/08/repurposing-scheme-2.jpg)
ENDD has partnered with Panorama Medicine to repurpose FDA-approved compounds for both STXBP1 and SYNGAP1 disorders. After screening thousands of compounds, we have identified several FDA-approved lead candidates that are blood-brain barrier penetrant and can upregulate target gene expression. We are currently testing them in our animal models for efficacy, phenotype rescue, and toxicology.